Multibic (Sodium Hydrogen Carbonate, Magnesium Chloride Hexahydrate, Sodium Chloride, Calcium Chloride Dihydra)

The active ingredients—sodium hydrogen carbonate, magnesium chloride, sodium chloride and calcium chloride—provide essential ions directly into the bloodstream. These ions replace those removed during dialysis or lost in clinical situations, buffering hydrogen ions to correct acidosis and stabilising electrolyte concentrations critical for cardiac, neuromuscular and renal function.

The dose of Multibic is individualized by the prescribing clinician based on the patient’s electrolyte profile, dialysis prescription and clinical condition. Healthcare professionals determine the infusion volume, rate and duration to achieve the desired electrolyte and acid‑base targets.

Safety data for Multibic in pregnancy and lactation are limited. It should only be used when clearly indicated and after a risk‑benefit assessment by the treating physician. The prescriber must consider the potential impact on maternal and fetal electrolyte balance before initiating therapy.

To order Multibic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Multibic offers a balanced combination of sodium, chloride, calcium, magnesium and bicarbonate, similar to many commercial dialysis fluids. Its formulation is designed to provide comprehensive electrolyte replacement in a single solution, potentially reducing the need for multiple adjunctive infusions compared with fluids that lack one or more of these ions.

Multibic should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture, direct sunlight and extreme temperature fluctuations. Ensure the container is sealed when not in use to maintain sterility.

Multibic is administered intravenously, either as a component of the dialysis circuit during haemodialysis or as a separate IV infusion for electrolyte replacement. The infusion rate and volume are set by the clinician according to the patient’s laboratory results and clinical needs.

Serious risks include severe hypermagnesemia, hypercalcemia, profound metabolic alkalosis, anaphylactic reactions and significant fluid overload leading to pulmonary edema. Continuous monitoring of electrolytes, acid‑base status and fluid balance is essential to detect and manage these complications promptly.

Multibic is contraindicated in patients with known hypersensitivity to any of its components. It should be used with caution, or avoided, in individuals with severe hypernatremia, uncontrolled hypercalcemia, severe cardiac arrhythmias, or those for whom fluid overload would pose a high risk.